UPDATE 1-U.S. FDA panel meets to discuss Sarepta muscular dystrophy drug

April 25 (Reuters) - Hundreds of patients and advocates packed a hotel ballroom in Hyattsville, Maryland, on Monday to try to persuade advisers to the U.S. Food and Drug Administration to support approval of an experimental drug to treat Duchenne muscular dystrophy.